Suzhou Health Science

Health Science (Suzhou) Co., Ltd. is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative vaccines and therapeutic antibodies. The company leverages its proprietary recombinant protein expression and novel adjuvant platforms to address significant unmet needs in infectious disease prevention. Its lead candidate, HS-001, is a next-generation recombinant human rabies vaccine currently in Phase 3 clinical trials, designed to provide superior safety and consistency compared to traditional vaccines. The company's pipeline also includes a recombinant shingles vaccine (HS-002) and candidates for norovirus and HPV. With integrated R&D and GMP manufacturing capabilities, Health Science (Suzhou) aims to become a leader in the global vaccine market.